Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | SAT1 | P21673 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL849696 | 0.81 | ANPEP (0.50) | ANPEPBTKEPHX2CYP4F2CYP4A11 | |
| SCHEMBL848937 | 0.78 | CYP1A2 (0.48) | ANPEPBTKCYP4F2CYP4A11EPHX1 | |
| SCHEMBL10709582 | 0.77 | ANPEP (0.53) | ANPEPBTKEPHX2CYP4F2CYP4A11 | |
| SCHEMBL8396708 | 0.76 | — | — | |
| SCHEMBL11593168 | 0.75 | ANPEP (0.45) | ANPEPBTKCYP4F2CYP4A11EPHX1 | |
| SCHEMBL849434 | 0.75 | ANPEP (0.45) | ANPEPBTKCYP4F2CYP4A11EPHX1 | |
| SCHEMBL10689965 | 0.75 | ANPEP (0.45) | ANPEPBTKCYP4F2CYP4A11EPHX1 | |
| SCHEMBL9820911 | 0.74 | ANPEP (0.44) | ANPEPBTKCYP4F2CYP4A11EPHX1 | |
| SCHEMBL9504414 | 0.74 | ANPEP (0.54) | ANPEPBTKEPHX2CYP4F2CYP4A11 | |
| SCHEMBL9504422 | 0.74 | ANPEP (0.54) | ANPEPBTKEPHX2CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210001023-A1 | EXTRACORPOREAL DEVICE AND MATRIX FOR REMOVING FIBRINOLYTIC PROTEINS FROM BIOLOGICAL FLUIDS, METHODS AND USES THEREOF | PLAS-FREE LTD (IL) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210001023-A1 | EXTRACORPOREAL DEVICE AND MATRIX FOR REMOVING FIBRINOLYTIC PROTEINS FROM BIOLOGICAL FLUIDS, METHODS AND USES THEREOF | PLG, FGB, PLAU | ANPEP 40/4885BTK 829/4885EPHX2 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.